Lenvatinib
- Generic Name
- Lenvatinib
- Brand Names
- Lenvima 10, Kisplyx, Lenvima
- Drug Type
- Small Molecule
- Chemical Formula
- C21H19ClN4O4
- CAS Number
- 417716-92-8
- Unique Ingredient Identifier
- EE083865G2
- Background
Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular ...
- Indication
Lenvatinib is indicated for the treatment of the following cancerous conditions:
Differentiated Thyroid Cancer (DTC)
Renal Cell Carcinoma (RCC)
Hepatocellular Carcinoma (HCC)
Endometrial Carcinoma
- Associated Conditions
- Advanced Renal Cell Carcinoma, Endometrial Carcinoma, Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally advanced radioactive iodine-refractory Differentiated Thyroid Cancer (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Cancer (DTC)
- Associated Therapies
- -
Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2016-10-17
- Last Posted Date
- 2022-05-31
- Target Recruit Count
- 20
- Registration Number
- NCT02935309
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
The Drug Rediscovery Protocol (DRUP Trial)
- Conditions
- Interventions
- Drug: PanitumumabDrug: OlaparibDrug: CrizotinibDrug: ErlotinibDrug: AlectinibDrug: Ipilimumab and nivolumabDrug: SunitinibDrug: Trastuzumab and Pertuzumab (combination treatment)Drug: Vemurafenib and Cobimetinib (combination treatment)Drug: NivolumabDrug: Dabrafenib and trametinibDrug: SelpercatinibDrug: TepotinibDrug: AbemaciclibDrug: ErdafitinibDrug: Atezolizumab and BevacizumabDrug: DacomitinibDrug: DabrafenibDrug: NilotinibDrug: TrametinibDrug: VismodegibDrug: RegorafenibDrug: AfatinibDrug: RibociclibDrug: LenvatinibDrug: PembrolizumabDrug: DurvalumabDrug: RucaparibDrug: AxitinibDrug: PalbociclibDrug: CabozantinibDrug: EntrectinibDrug: TalazoparibDrug: LorlatinibDrug: AlpelisibDrug: NiraparibDrug: Pemigatinib
- First Posted Date
- 2016-10-05
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 1550
- Registration Number
- NCT02925234
- Locations
- 🇳🇱
Meander medisch centrum, Amersfoort, Netherlands
🇳🇱Netherlands Cancer Institute, Amsterdam, Netherlands
🇳🇱Amsterdam UMC, locatie AMC, Amsterdam, Netherlands
A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease
- Conditions
- Interventions
- First Posted Date
- 2016-09-27
- Last Posted Date
- 2023-01-17
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT02915783
- Locations
- 🇺🇸
Washington University, Saint Louis, Missouri, United States
🇺🇸Huntsman Cancer Institute, Salt Lake City, Utah, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
Lenvatinib and Capecitabine in Patients With Advanced Malignancies
- Conditions
- Malignant Neoplasm of BreastMalignant Neoplasms of Digestive OrgansMalignant Neoplasms of Mesothelial and Soft TissueAdvanced CancerMalignant Neoplasms of Bone and Articular CartilageMalignant Neoplasms of Eye Brain and Other Parts of Central Nervous SystemMalignant Neoplasms of Female Genital OrgansMalignant Neoplasms of Independent (Primary) Multiple SitesMalignant Neoplasms of Urinary TractMalignant Neoplasms of Lip Oral Cavity and Pharynx
- Interventions
- First Posted Date
- 2016-09-26
- Last Posted Date
- 2017-06-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT02915172
Lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinomas of the Salivary Glands: ACC-LEN14
- Conditions
- Interventions
- First Posted Date
- 2016-08-10
- Last Posted Date
- 2019-09-03
- Target Recruit Count
- 26
- Registration Number
- NCT02860936
- Locations
- 🇮🇹
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
- Conditions
- Interventions
- Biological: Pembrolizumab 200 mgBiological: Pembrolizumab/Vibostolimab coformulationBiological: Belzutifan 120mgDrug: Olaparib 400 mgDrug: Docetaxel 75 mg/m^2Drug: Enzalutamide 160 mgDrug: LenvatinibDrug: CarboplatinDrug: Olaparib 300 mgDrug: Prednisone 5 mgDrug: Abiraterone acetate 1000 mgDrug: EtoposideOther: Dexamethasone 8 mg
- First Posted Date
- 2016-08-10
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1200
- Registration Number
- NCT02861573
- Locations
- 🇨🇳
Merck Sharp & Dohme (I.A.) Corp., Taipei, Taiwan
🇺🇸Call for Information (Investigational Site 0005), Los Angeles, California, United States
🇺🇸Call for Information (Investigational Site 2041), Aurora, Colorado, United States
Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling
- First Posted Date
- 2016-07-27
- Last Posted Date
- 2018-08-02
- Lead Sponsor
- Teresa Helsten, MD
- Registration Number
- NCT02846766
- Locations
- 🇺🇸
University of California, San Diego, La Jolla, California, United States
🇺🇸Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, United States
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2016-06-23
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 1069
- Registration Number
- NCT02811861
- Locations
- 🇮🇱
Chaim Sheba Medical Center, Ramat-Gan, Israel
🇯🇵Facility #2, Tokyo, Japan
🇺🇸Mount Sinai Medical Center, Miami Beach, Florida, United States
Crossover Study to Evaluate the Relative Bioavailability and Palatability of a Lenvatinib Suspension Compared to the Capsule Formulation in Adult Healthy Volunteers
- First Posted Date
- 2016-06-08
- Last Posted Date
- 2019-03-14
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT02792829
Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma
- First Posted Date
- 2016-05-23
- Last Posted Date
- 2024-06-05
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 33
- Registration Number
- NCT02780310
- Locations
- 🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.